SEC Comment Letter for Forte Biosciences, Inc. (FBRX) (CIK 0001419041) (FBRX) — May 22, 2018
Forte Biosciences, Inc. (FBRX) (CIK 0001419041)
Date: May 22, 2018 · CIK: 0001419041 · Accession: 0000000000-18-015792
AI Filing Summary & Sentiment
File numbers found in text: 333-224880
Letter
May 21, 2018 Martin J. Duvall Chief Executive Officer Tocagen Inc. 3030 Bunker Hill Street, Suite 230 San Diego, CA 92109 Re:Tocagen Inc. Registration Statement on Form S-3 Filed May 11, 2018 File No. 333-224880 Dear Mr. Duvall: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at (202) 551-5019 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Karen Deschaine Anderson, Esq.
Show Raw Text
May 21, 2018
Martin J. Duvall
Chief Executive Officer
Tocagen Inc.
3030 Bunker Hill Street, Suite 230
San Diego, CA 92109
Re:Tocagen Inc.
Registration Statement on Form S-3
Filed May 11, 2018
File No. 333-224880
Dear Mr. Duvall:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at (202) 551-5019 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Karen Deschaine Anderson, Esq.